TR200102436T2 - 5-HT1F agonists - Google Patents

5-HT1F agonists

Info

Publication number
TR200102436T2
TR200102436T2 TR2001/02436T TR200102436T TR200102436T2 TR 200102436 T2 TR200102436 T2 TR 200102436T2 TR 2001/02436 T TR2001/02436 T TR 2001/02436T TR 200102436 T TR200102436 T TR 200102436T TR 200102436 T2 TR200102436 T2 TR 200102436T2
Authority
TR
Turkey
Prior art keywords
ht1f agonists
ht1f
agonists
vascularization
mammal
Prior art date
Application number
TR2001/02436T
Other languages
Turkish (tr)
Inventor
Ann Filla Sandra
Michael Mathes Brian
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200102436T2 publication Critical patent/TR200102436T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Abstract

Bu bulus, bir memelide 4-HT1F reseptörlerinin aktive edilmesinde ve nöron proteininin damar disina sizmasinin inhibe edilmesinde faydali olan, formül (i)'e sahip bir bilesige veya bunun farmasötik bir asit ilave iliskindir.This invention relates to a compound of formula (i) or a pharmaceutical acid addition thereof that is useful in activating 4-HT1F receptors in a mammal and inhibiting non-vascularization of neuron protein.

TR2001/02436T 1999-02-26 2000-02-11 5-HT1F agonists TR200102436T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12201699P 1999-02-26 1999-02-26

Publications (1)

Publication Number Publication Date
TR200102436T2 true TR200102436T2 (en) 2002-06-21

Family

ID=22400069

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02436T TR200102436T2 (en) 1999-02-26 2000-02-11 5-HT1F agonists

Country Status (21)

Country Link
EP (1) EP1155020B1 (en)
JP (1) JP2002537398A (en)
KR (1) KR20010102355A (en)
AR (1) AR026856A1 (en)
AT (1) ATE258935T1 (en)
AU (1) AU3354000A (en)
BR (1) BR0008479A (en)
CA (1) CA2371784A1 (en)
CO (1) CO5150234A1 (en)
DE (1) DE60008073T2 (en)
EA (1) EA200100918A1 (en)
ES (1) ES2214256T3 (en)
HU (1) HUP0200245A2 (en)
ID (1) ID30056A (en)
IL (1) IL144355A0 (en)
NO (1) NO20014127D0 (en)
PE (1) PE20001432A1 (en)
PL (1) PL350864A1 (en)
TR (1) TR200102436T2 (en)
WO (1) WO2000050426A2 (en)
ZA (1) ZA200106109B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
CN1777584A (en) 2003-04-18 2006-05-24 伊莱利利公司 (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht 1f agonists
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
WO2005061439A1 (en) 2003-12-17 2005-07-07 Eli Lilly And Company Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists
CA2795062A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
EP2940022B1 (en) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
AR119319A1 (en) 2019-07-09 2021-12-09 Lilly Co Eli PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-IL]-BENZAMIDE HEMISUCCINATE AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-IL]-BENZAMIDE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001113B1 (en) * 1995-03-20 2000-10-30 Эли Лилли Энд Компани 5-substituted -3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles and their pharmaceutically acceptable salts and solvates, pharmaceutical composition on their basem method for activation of 5-ht receptors, and method for inhibition of neuronal protein extravasation
FR2732969B1 (en) * 1995-04-14 1997-05-16 Adir NOVEL PYRIDINIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1998011895A1 (en) * 1996-09-18 1998-03-26 Eli Lilly And Company A method for the prevention of migraine

Also Published As

Publication number Publication date
WO2000050426A2 (en) 2000-08-31
HUP0200245A2 (en) 2002-06-29
WO2000050426A3 (en) 2000-12-21
ZA200106109B (en) 2002-07-25
AU3354000A (en) 2000-09-14
CA2371784A1 (en) 2000-08-31
CO5150234A1 (en) 2002-04-29
PE20001432A1 (en) 2000-12-18
PL350864A1 (en) 2003-02-10
EP1155020A2 (en) 2001-11-21
EP1155020B1 (en) 2004-02-04
IL144355A0 (en) 2002-05-23
ES2214256T3 (en) 2004-09-16
DE60008073D1 (en) 2004-03-11
KR20010102355A (en) 2001-11-15
DE60008073T2 (en) 2004-08-05
NO20014127L (en) 2001-08-24
NO20014127D0 (en) 2001-08-24
AR026856A1 (en) 2003-03-05
ATE258935T1 (en) 2004-02-15
BR0008479A (en) 2002-01-29
ID30056A (en) 2001-11-01
EA200100918A1 (en) 2002-02-28
JP2002537398A (en) 2002-11-05

Similar Documents

Publication Publication Date Title
AU4831899A (en) 5-HT1F agonists
HUP0203939A2 (en) Pharmaceutical compounds and compositions containing them and their use
ATE236890T1 (en) OXYGEN OR SULFUR CONTAINING 5-MEMBED HETEROAROMATIC DERIVATIVES AS FACTOR XA INHIBITORS
TR200101899T2 (en) Thrombin inhibitors.
DK1629849T3 (en) Pharmaceutical compositions containing exendins and their agonists
TR200003632T2 (en) Benzothioepine-1,1-dioxide derivatives, method of production, drugs containing them.
TNSN02010A1 (en) NOVEL PYRIMIDINE DERIVATIVES OF MMP INHIBITORS, AND COMPOSITIONS CONTAINING THEM
TR199902946T2 (en) Derived 3-cyano quinolines.
TR200202806T2 (en) 4-Trifluoromethylsulfinylpyrazole derivative preparation process
ATE377000T1 (en) 5-HT1F AGONISTS
TR200100047T2 (en) Thiobenzimidazole derivatives
TR200200581T2 (en) Compositions and treatment methods containing isoflavones and their analogues
DE69200959T2 (en) N-ACYL DERIVATIVES OF AMINO ACID MIXTURES OBTAINED FROM CEREAL PROTEIN HYDROLYSATES AND THEIR APPLICATIONS.
ATE241616T1 (en) MODIFIED AMINO ACID AMIDES AS CGRP ANTAGONISTS
MY136141A (en) Novel hydantoin derivatives and pharmaceutical compositions useful as metalloproteinase inhibitors
TR200000132T2 (en) Dolastatin 15 derivatives
ATE319437T1 (en) USES OF PPAR-GAMMA AGONISTS IN NEUTROPHIL CAUSED DISEASES
TR200102436T2 (en) 5-HT1F agonists
WO2000006173A8 (en) 5-ht1f agonists
ATE248832T1 (en) ANTAGONISTS OF GONADOTROPIN-RELEASE HORMON
DE69929703D1 (en) NEW ORAL FORMULATIONS FOR 5-HT4 AGONISTS OR ANTAGONISTS
TR199900719A2 (en) Derivatives of phenoxy acetic acid and phenoxymethyl tetrazole.
TR199902151T2 (en) Low aqueous diamine/dicarboxylic acid salt.
DE60039631D1 (en) CYCLOPENTYL SULFONAMIDE DERIVATIVES
TR199902971T2 (en) Aryl substituted piperazines useful in the treatment of benign prostatic hyperplasia.